Faculty Collaboration Database

Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010 Dec;16(12):1693-9

Date

06/15/2010

Pubmed ID

20541024

Pubmed Central ID

PMC2955996

DOI

10.1016/j.bbmt.2010.05.019

Scopus ID

2-s2.0-78149414023 (requires institutional sign-in at Scopus site)   82 Citations

Abstract

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to reliably categorize patients at high risk for death or to promptly identify those who might benefit from alternate treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival. We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response (complete or partial response) best categorized patients by NRM and survival at 9 months from start of aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.

Author List

Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D, Blood and Marrow Transplant Clinical Trials Network

Author

Brent R. Logan PhD Director, Professor in the Institute for Health and Equity department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adrenal Cortex Hormones
Adult
Diphtheria Toxin
Etanercept
Graft vs Host Disease
Hematologic Diseases
Hematopoietic Stem Cell Transplantation
Humans
Immunoglobulin G
Interleukin-2
Methylprednisolone
Middle Aged
Pentostatin
Receptors, Tumor Necrosis Factor
Recombinant Fusion Proteins
Survival Analysis
Treatment Outcome